Rallybio Drops 9.98% Despite Q1 Progress, Recursion Deal

Rallybio's stock experienced a significant drop of 9.98% in pre-market trading on July 9, 2025, reflecting investor sentiment and market dynamics.

Rallybio recently reported its Q1 2025 financial results and business updates, highlighting the advancement of RLYB116 into a confirmatory PK/PD study in Q2 2025. This development is crucial for the company's pipeline and investor confidence.

The company's strategic decision to sell its interest in the REV102 program to Recursion has extended its cash runway into mid-2027. This move not only provides immediate financial relief but also allows Rallybio to focus on its core assets and development programs.

Despite the recent sell-off, Rallybio's stock has shown resilience, with significant gains following the announcement of the deal with Recursion. The upfront payment of $7.5 million and potential future milestones have bolstered investor optimism about the company's future prospects.